Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Infect Disord Drug Targets. 2021;21(6):e170721187996. doi: 10.2174/1871526520666201116100310

Fig. (2).

Fig. (2).

MMP3 inhibition during the exudative phase of ARDS will reduce vascular injury and alveolar edema and prevent the disease progression to the irreversible stages of the disease.